[go: up one dir, main page]

WO2005113598A3 - Tnf super family members with altered immunogenicity - Google Patents

Tnf super family members with altered immunogenicity Download PDF

Info

Publication number
WO2005113598A3
WO2005113598A3 PCT/US2005/018130 US2005018130W WO2005113598A3 WO 2005113598 A3 WO2005113598 A3 WO 2005113598A3 US 2005018130 W US2005018130 W US 2005018130W WO 2005113598 A3 WO2005113598 A3 WO 2005113598A3
Authority
WO
WIPO (PCT)
Prior art keywords
super family
family members
altered immunogenicity
tnf super
relates
Prior art date
Application number
PCT/US2005/018130
Other languages
French (fr)
Other versions
WO2005113598A2 (en
Inventor
Shannon Alicia Marshall
Gregory L Moore
Arthur J Chirino
John R Desjarlais
Original Assignee
Xencor Inc
Shannon Alicia Marshall
Gregory L Moore
Arthur J Chirino
John R Desjarlais
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xencor Inc, Shannon Alicia Marshall, Gregory L Moore, Arthur J Chirino, John R Desjarlais filed Critical Xencor Inc
Publication of WO2005113598A2 publication Critical patent/WO2005113598A2/en
Publication of WO2005113598A3 publication Critical patent/WO2005113598A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention relates to non-naturally occurring variant Tumor Necrosis Factor Super Family member proteins with reduced immunogenicity. More specifically, the present invention relates to variant BAFF, RANKL, TRAIL, CD40L and APRIL proteins with reduced immunogenicity.
PCT/US2005/018130 2004-05-21 2005-05-23 Tnf super family members with altered immunogenicity WO2005113598A2 (en)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US57330104P 2004-05-21 2004-05-21
US57339504P 2004-05-21 2004-05-21
US57320604P 2004-05-21 2004-05-21
US60/573,395 2004-05-21
US60/573,206 2004-05-21
US60/573,301 2004-05-21
US58831404P 2004-07-14 2004-07-14
US60/588,314 2004-07-14
US60739604P 2004-09-02 2004-09-02
US60739704P 2004-09-02 2004-09-02
US60/607,397 2004-09-02
US60/607,396 2004-09-02

Publications (2)

Publication Number Publication Date
WO2005113598A2 WO2005113598A2 (en) 2005-12-01
WO2005113598A3 true WO2005113598A3 (en) 2006-06-01

Family

ID=35428917

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/018130 WO2005113598A2 (en) 2004-05-21 2005-05-23 Tnf super family members with altered immunogenicity

Country Status (1)

Country Link
WO (1) WO2005113598A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080074120A (en) 2005-10-13 2008-08-12 휴먼 게놈 사이언시즈, 인코포레이티드 Methods and compositions for use in treatment of patients with autoantibody positive diseases
MY183797A (en) 2006-09-18 2021-03-16 Univ Arkansas Compositions and methods of enhancing immune responses
NZ585776A (en) 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
CN101969990B (en) 2007-11-01 2014-07-09 阿肯色大学评议会 Compositions and methods for enhancing immune responses against Eimeria
EA023058B1 (en) 2010-01-21 2016-04-29 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас Vaccine vectors and methods of enhancing immune responses
UA116915C2 (en) 2010-06-09 2018-05-25 Дзе Борд Оф Трастіз Оф Дзе Юніверсіті Оф Арканзас A VECTOR CODING AN ANTIGENIC peptide AND A METHOD OF IMPROVING INFLUENCE OF CAMPYLOBACTER INFECTIONS
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
MY173901A (en) 2013-03-15 2020-02-26 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to enteric pathogens
AU2017260323B2 (en) 2016-05-03 2023-11-16 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same
IL303992A (en) * 2020-12-29 2023-08-01 Cemm Forschungszentrum F?R Molekulare Medizin Gmbh Anti-april antibodies and uses thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012965A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. April- a novel protein with growth effects
WO2000067034A1 (en) * 1999-04-30 2000-11-09 Immunex Corporation Methods of use of the taci/taci-l interaction
WO2002018445A2 (en) * 2000-09-01 2002-03-07 Biogen, Inc. Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002036141A2 (en) * 2000-11-02 2002-05-10 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
US20020061525A1 (en) * 2000-05-16 2002-05-23 Rodrigo Yelin Sequences of trail variants
WO2003006154A2 (en) * 2001-07-10 2003-01-23 Xencor, Inc. Protein design automation for designing protein libraries with altered immunogenicity
WO2003029420A2 (en) * 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
WO2003059281A2 (en) * 2002-01-04 2003-07-24 Xencor Novel variants of rankl protein
WO2004081043A2 (en) * 2003-01-06 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
WO2005035570A2 (en) * 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012965A2 (en) * 1997-09-12 1999-03-18 Biogen, Inc. April- a novel protein with growth effects
WO2000067034A1 (en) * 1999-04-30 2000-11-09 Immunex Corporation Methods of use of the taci/taci-l interaction
US20020061525A1 (en) * 2000-05-16 2002-05-23 Rodrigo Yelin Sequences of trail variants
WO2002018445A2 (en) * 2000-09-01 2002-03-07 Biogen, Inc. Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design
WO2002036141A2 (en) * 2000-11-02 2002-05-10 Immunex Corporation Method of enhancing lymphocyte-mediated immune responses
WO2003006154A2 (en) * 2001-07-10 2003-01-23 Xencor, Inc. Protein design automation for designing protein libraries with altered immunogenicity
WO2003029420A2 (en) * 2001-10-02 2003-04-10 Genentech, Inc. Apo-2 ligand variants and uses thereof
WO2003059281A2 (en) * 2002-01-04 2003-07-24 Xencor Novel variants of rankl protein
WO2004081043A2 (en) * 2003-01-06 2004-09-23 Xencor, Inc. Baff mutants with at least one amino acid substitution and methods of their production
WO2004089982A2 (en) * 2003-01-06 2004-10-21 Xencor April variants and methods thereof
WO2005035570A2 (en) * 2003-10-10 2005-04-21 Xencor, Inc. Variants of cd40l protein

Also Published As

Publication number Publication date
WO2005113598A2 (en) 2005-12-01

Similar Documents

Publication Publication Date Title
WO2006105338A3 (en) Fc VARIANTS WITH OPTIMIZED PROPERTIES
WO2004075861A3 (en) Recombinant adeno-associated virus production
WO2006076594A3 (en) Antibodies and fc fusion proteins with altered immunogenicity
WO2007073548A3 (en) Embolic coils coated with alginate and polyvinylalcohol
AU2006272804A8 (en) Concentrated protein lyophilates, methods, and uses
WO2005056759A3 (en) Methods of generating variant proteins with increased host string content and compositions thereof
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2006009888A3 (en) C-met kinase binding proteins
WO2008140493A3 (en) Anti-egfr family antibodies, bispecific anti-egfr family antibodies and methods of use thereof
WO2006010057A3 (en) Therapeutic peptides
WO2007009018A3 (en) Il-6 binding proteins
WO2005113598A3 (en) Tnf super family members with altered immunogenicity
WO2004031352A3 (en) Interferon variants with improved properties
WO2006070023A3 (en) Method for reversing multiple resistance in animal cells
AP2415A (en) Bacteriocin Inducer peptides.
WO2005076696A3 (en) Pneumolysin derivatives
WO2006029398A8 (en) All-trans-retinol : all-trans-13,14-dihydroretinol saturase and methods of its use
WO2003059281A3 (en) Novel variants of rankl protein
WO2008108660A3 (en) Fish disease detection
WO2006013462A3 (en) Growth factors nsg28, nsg30, and nsg32
中林雅士 The complete works of Raymond Carver
Corliss The Best Movies of 2004
Aksyutin et al. About the LUE-300 Accelerator Operation in 2006; O rabote uskoritelya LUEh-300 v 2006 godu
Barood Jerusalem: Settlements and Judization
WO2006124843A3 (en) Polyester-urethane (meth) acrylate resins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase